Back to Browse Journals » OncoTargets and Therapy » Volume 3

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine

Authors Steven E McCormack, Erica D Warlick

Published Date July 2010 Volume 2010:3 Pages 157—165

DOI http://dx.doi.org/10.2147/OTT.S5852

Published 22 July 2010

Steven E McCormack, Erica D Warlick

Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA

Abstract: Myelodysplastic syndromes (MDS) are a varied group of diseases leading to ­significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option. Agents, such as the cytidine analog azacitidine, exert an effect on DNA methyltransferase leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of MDS. Recently, azacitidine has been shown to prolong survival and improve quality of life in patients with MDS, while maintaining a favorable adverse effect profile. This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS.

Keywords: hypomethylation, epigenetics, myelodysplastic syndromes, azacitidine

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1579-1584

Published Date: 25 September 2012

Central retinal artery occlusion in a patient with ANCA-negative Churg-Strauss syndrome

Kumano Y, Yoshida N, Fukuyama S, Miyazaki M, Enaida H, Matsui T

Clinical Ophthalmology 2012, 6:1225-1228

Published Date: 31 July 2012

Application of reticulated platelets to transfusion management during autologous stem cell transplantation

Parco S, Vascotto F

OncoTargets and Therapy 2012, 5:1-5

Published Date: 26 January 2012

Outcomes of 23-gauge pars plana vitrectomy in vitreoretinal diseases

Sezgin Akçay B, Uyar OM, Akkan F, Eltutar K

Clinical Ophthalmology 2011, 5:1771-1776

Published Date: 14 December 2011

Influence of optic disc size on the diagnostic performance of macular ganglion cell complex and peripapillary retinal nerve fiber layer analyses in glaucoma

Cordeiro DV, Lima VC, Castro DP, Castro LC, Pacheco MA, Lee JM, Dimantas MI, Prata TS

Clinical Ophthalmology 2011, 5:1333-1337

Published Date: 19 September 2011

Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method

Zaida Urbán-Morlán, Adriana Ganem-Rondero, Luz María Melgoza-Contreras, et al

International Journal of Nanomedicine 2010, 5:611-620

Published Date: 19 August 2010

Treatment of retinal pigment epithelial detachment with antiangiogenic therapy

Luis Arias

Clinical Ophthalmology 2010, 4:369-374

Published Date: 16 April 2010